EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis

Takeshi Murata, Masayuki Yoshida, Chikashi Watase, Hinako Maeda, Ayako Nakashoji, Ayumi Ogawa, Natsuko Ohgi, Mengge Chen, Sayako Tsubota, Akiko Maeshima, Eriko Iwamoto, Shin Takayama

Breast Cancer · 2026-07 · 33 (4) · 928-937

DOI: 10.1007/s12282-026-01871-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Breast Cancer, online erschienen am 23.05.2026. Verfasst von Takeshi Murata und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tamurata@ncc.go.jp. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Micrometastasis, Erb-b2 Receptor Tyrosine Kinases, Lymph Nodes. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm MicrometastasisErb-b2 Receptor Tyrosine KinasesLymph NodesNeoplasm Recurrence, LocalHumansFemalePrognosisRetrospective StudiesLymphatic MetastasisMiddle AgedReceptors, ProgesteroneReceptors, EstrogenAdultAgedAxillaDisease-Free Survival

Stichwörter der Autor:innen

Breast cancerHER2-negativeHormone receptor-positiveMicrometastasisNode-positive

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanReceptors, ProgesteroneReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tamurata@ncc.go.jp.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo- ku, Tokyo, 104-0045, Japan.
  • Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Zitieren

APA

Murata, T., Yoshida, M., Watase, C., Maeda, H., Nakashoji, A., Ogawa, A., Ohgi, N., Chen, M., Tsubota, S., Maeshima, A., Iwamoto, E., & Takayama, S. (2026). Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis. Breast Cancer, 33(4), 928-937. https://doi.org/10.1007/s12282-026-01871-2

Vancouver

Murata T, Yoshida M, Watase C, Maeda H, Nakashoji A, Ogawa A, et al. Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis. Breast Cancer. 2026;33(4):928-937. doi:10.1007/s12282-026-01871-2

BibTeX
@article{Murata2026,
  author = {Murata, Takeshi and Yoshida, Masayuki and Watase, Chikashi and Maeda, Hinako and Nakashoji, Ayako and Ogawa, Ayumi and Ohgi, Natsuko and Chen, Mengge and Tsubota, Sayako and Maeshima, Akiko and Iwamoto, Eriko and Takayama, Shin},
  title = {Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis},
  journal = {Breast Cancer},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {928--937},
  doi = {10.1007/s12282-026-01871-2}
}
Kostenlos starten →